Q2 2012 · —
Revenue$124.23M$124.23M +92.4% vs Q2 2011+21.2% vs Q1 2012
Net Income$27.15M$27.15M −18.2% vs Q2 2011−1.9% vs Q1 2012
EPS Diluted$0.45$0.45 −36.6% vs Q2 2011−6.2% vs Q1 2012
Gross Profit$110,714,000+84.2%
Operating Income$39,427,000+16.4%
Operating Cash Flowderived$76,969,000+105.6%
Free Cash Flowderived$74,760,000+100.2%
Margins · derived
Gross margin89.1%−4.0 pt vs Q2 2011
Operating margin31.7%−20.7 pt vs Q2 2011
Net margin21.9%−29.6 pt vs Q2 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2012 | Q2 2011 | Q2 2010 |
|---|---|---|---|
| Revenue | $124.23M | $64.57M | $64.57M |
| Net Income | $27.15M | $33.20M | $33.20M |
| EPS Diluted | $0.45 | $0.71 | $0.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR